Top Markets
#1 Zora Zora +43.81%
#2 AI XOVIA AI XOVIA +37.42%
#3 0G 0G +21.07%
#4 Full Moon Full Moon +19.35%
#5 Axelar Axelar +17.04%
#6 Notcoin Notcoin +13.85%
#7 ZKsync ZKsync +12.68%
#8 Wrapped NXM Wrapped NXM +12.14%
#9 rsERG rsERG +12.06%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +10.43%
Coin of the day
Zora Zora
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Silence Therapeutics plc Silence Therapeutics plc

Silence Therapeutics plc

SLN
Classifica tra le azioni #12014
Silence Therapeutics plc is a London, UK-based biotechnology company... Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
Prezzo delle azioni
$13.34
Ultima sincronizzazione: 2026-08-28
Capitalizzazione di mercato
$629.93M
Variazione (1 giorno)
-0.84%
Variazione (1 anno)
177.26%
Paese
GB
Scambia Silence Therapeutics plc (SLN)

Categoria

Healthcare
Utile per Silence Therapeutics plc (SLN)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Silence Therapeutics plc, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Silence Therapeutics plc dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH